LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Home・Aandelen Lijst・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

43.42 0.37

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

42.61

Max

44.43

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.2M -91M
Winstmarge	-867.293
Werknemers	316
EBITDA	4M -90M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+27.73% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	211M 3.4B
Vorige openingsprijs	43.05
Vorige sluitingsprijs	43.42

Nieuwssentiment

By Acuity

25%

75%

116 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.81 / 38.24 Steun & Weerstand

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 dec 2025, 23:58 UTC

Acquisities, Fusies, Overnames

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11 dec 2025, 23:56 UTC

Winsten

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11 dec 2025, 23:03 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dec 2025, 21:50 UTC

Winsten

Costco Same-Store Sales, Membership Fees Rose in 1Q

11 dec 2025, 23:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

11 dec 2025, 23:44 UTC

Marktinformatie

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11 dec 2025, 23:37 UTC

Marktinformatie

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11 dec 2025, 23:31 UTC

Winsten

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dec 2025, 22:48 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11 dec 2025, 22:35 UTC

Winsten

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11 dec 2025, 22:30 UTC

Winsten

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11 dec 2025, 22:09 UTC

Acquisities, Fusies, Overnames

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11 dec 2025, 22:05 UTC

Winsten

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dec 2025, 21:51 UTC

Acquisities, Fusies, Overnames

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

11 dec 2025, 21:39 UTC

Winsten

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11 dec 2025, 21:39 UTC

Winsten

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11 dec 2025, 21:38 UTC

Winsten

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11 dec 2025, 21:37 UTC

Winsten

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11 dec 2025, 21:37 UTC

Marktinformatie

Broadcom Sees AI Revenue Doubling -- Market Talk

11 dec 2025, 21:34 UTC

Acquisities, Fusies, Overnames

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

Dexus Aiming for Long-Term Holding of A$50M in Fund

11 dec 2025, 21:28 UTC

Marktinformatie

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Dexus: Third Party Investors to Contribute Remainder

11 dec 2025, 21:27 UTC

Acquisities, Fusies, Overnames

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11 dec 2025, 21:25 UTC

Acquisities, Fusies, Overnames

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

27.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 55.59 USD 27.73%

Hoogste 65 USD

Laagste 44 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Gebaseerd op 14 analisten die aandelenratings hebben gegeven aan Xenon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

116 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.